Seinda Pharmaceutical Corp.

Seinda is a precision Dx–Rx ophthalmology company uniquely positioned to deliver a disease-modifying therapy for Dry Eye Disease (DED). Built on deep mechanistic insight into ocular surface immunology, Seinda owns the global rights of a Phase 3-ready therapeutic asset with a clinically validated, commercial-stage tear diagnostics platform.

Seinda leading asset SY201 is a small peptide with novel multi-modal MOAs. In a completed U.S. Phase 2 trial, SY201 showed rapid and consistent improvements across both symptoms and signs, and excellent tolerability. These effects were repeatable across an investigator-initiated trial in China, de-risking Phase 3 and regulatory approval.

Importantly, Seinda integrated its tear biomarker diagnostic into the Phase 2 of SY201 and demonstrated that patients with elevated MMP-9 experienced greater clinical benefit. This Dx–Rx integration enhances regulatory success, and will strengthens the payer value proposition of SY201.